HomeCompareNXGT vs MRK

NXGT vs MRK: Dividend Comparison 2026

NXGT yields 25316.46% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NXGT wins by $545812235198788272128.00M in total portfolio value
10 years
NXGT
NXGT
● Live price
25316.46%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$545812235198788272128.00M
Annual income
$541,603,839,126,149,800,000,000,000.00
Full NXGT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NXGT vs MRK

📍 NXGT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXGTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXGT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXGT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXGT
Annual income on $10K today (after 15% tax)
$2,151,898.73/yr
After 10yr DRIP, annual income (after tax)
$460,363,263,257,227,300,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NXGT beats the other by $460,363,263,257,227,300,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXGT + MRK for your $10,000?

NXGT: 50%MRK: 50%
100% MRK50/50100% NXGT
Portfolio after 10yr
$272906117599394136064.00M
Annual income
$270,801,919,563,074,900,000,000,000.00/yr
Blended yield
99.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NXGT
No analyst data
Altman Z
-22.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXGT buys
0
MRK buys
0
No recent congressional trades found for NXGT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXGTMRK
Forward yield25316.46%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$545812235198788272128.00M$56.8K
Annual income after 10y$541,603,839,126,149,800,000,000,000.00$9,798.13
Total dividends collected$545535052761023643648.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NXGT vs MRK ($10,000, DRIP)

YearNXGT PortfolioNXGT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,542,346$2,531,645.57$11,206$366.19+$2.53MNXGT
2$604,245,347$601,525,037.18$12,650$502.35+$604.23MNXGT
3$134,259,526,671$133,612,984,149.75$14,407$694.19+$134259.51MNXGT
4$27,889,421,383,128$27,745,763,689,589.74$16,585$967.82+$27889421.37MNXGT
5$5,416,349,539,098,672$5,386,507,858,218,725.00$19,342$1,363.89+$5416349539.08MNXGT
6$983,461,915,432,174,600$977,666,421,425,338,900.00$22,913$1,947.19+$983461915432.15MNXGT
7$166,956,658,621,138,240,000$165,904,354,371,625,800,000.00$27,662$2,823.89+$166956658621138.22MNXGT
8$26,500,723,640,478,440,000,000$26,322,080,015,753,820,000,000.00$34,159$4,173.35+$26500723640478440.00MNXGT
9$3,933,080,441,718,197,000,000,000$3,904,724,667,422,885,000,000,000.00$43,337$6,308.80+$3933080441718196736.00MNXGT
10$545,812,235,198,788,300,000,000,000$541,603,839,126,149,800,000,000,000.00$56,776$9,798.13+$545812235198788272128.00MNXGT

NXGT vs MRK: Complete Analysis 2026

NXGTStock

Nexteligent Holdings, Inc. operates as an aggregator of healthcare professional services and technology firms. The company provides professional services in telemedicine, consulting, and financial management. Its Telemedicine Solutions division develops and manages remote care and technology programs aimed at containing costs, improving productivity, and enhancing the quality of medical encounters at healthcare institutions serving the eldercare sector, as well as municipalities and not-for-profit organizations. The company's Financial Services division provides end-to-end revenue cycle management solutions and denials recovery for hospital systems, doctor groups, clinics, and long term care operators. This division also offers turnkey solutions for preventative care services, such as chronic care management, annual wellness visit, transitional care management, behavioral health, and remote telemonitoring. Nexteligent Holdings, Inc. is headquartered in Avon, Connecticut.

Full NXGT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NXGT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXGT vs SCHDNXGT vs JEPINXGT vs ONXGT vs KONXGT vs MAINNXGT vs JNJNXGT vs ABBVNXGT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.